The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and Type 1 retinopathy of prematurity.


Çömez A., Karaküçük Y., Özmen M. C. , Çelemler P., Saygılı O.

Eye (London, England), vol.35, no.12, pp.3302-3310, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 12
  • Publication Date: 2021
  • Doi Number: 10.1038/s41433-021-01413-4
  • Journal Name: Eye (London, England)
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, Design & Applied Arts Index, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.3302-3310
  • Gazi University Affiliated: Yes

Abstract

Objectives This study evaluated the efficacy of intravitreal bevacizumab (IVB) monotherapy for aggressive posterior retinopathy of prematurity (APROP) and Type 1 retinopathy of prematurity (ROP), along with recurrence rates and treatment outcomes for recurrences.